433 related articles for article (PubMed ID: 30539465)
41. Combinations of Bevacizumab With Cancer Immunotherapy.
Chen DS; Hurwitz H
Cancer J; 2018; 24(4):193-204. PubMed ID: 30119083
[TBL] [Abstract][Full Text] [Related]
42. Anti-body building: The exercise of advancing immune based myeloma therapies.
Richter J; Thibaud S
Blood Rev; 2021 Jul; 48():100789. PubMed ID: 33384171
[TBL] [Abstract][Full Text] [Related]
43. Durvalumab in non-small-cell lung cancer patients: current developments.
Mezquita L; Planchard D
Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
[TBL] [Abstract][Full Text] [Related]
44. Clinical use of checkpoint inhibition in kidney cancer.
Clin Adv Hematol Oncol; 2016 Jun; 14(6):427-9. PubMed ID: 27379812
[No Abstract] [Full Text] [Related]
45. Interview with Thomas Powles: The use of durvalumab in urothelial cancer - the latest strides in immuno-oncology.
Powles T
Future Oncol; 2017 Aug; 13(18):1581-1583. PubMed ID: 28726491
[TBL] [Abstract][Full Text] [Related]
46. Cancer immune therapy for lymphoid malignancies: recent advances.
Klausen U; Jørgensen NGD; Grauslund JH; Holmström MO; Andersen MH
Semin Immunopathol; 2019 Jan; 41(1):111-124. PubMed ID: 30006739
[TBL] [Abstract][Full Text] [Related]
47. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic Antibodies in Cancer Therapy.
Gasser M; Waaga-Gasser AM
Adv Exp Med Biol; 2016; 917():95-120. PubMed ID: 27236554
[TBL] [Abstract][Full Text] [Related]
49. Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.
Zhang B; Li W; Fan D; Tian W; Zhou J; Ji Z; Song Y
Immunology; 2022 Sep; 167(1):15-27. PubMed ID: 35575882
[TBL] [Abstract][Full Text] [Related]
50. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies.
Swan D; Routledge D; Harrison S
Br J Haematol; 2022 Feb; 196(3):488-506. PubMed ID: 34472091
[TBL] [Abstract][Full Text] [Related]
51. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
Colombo MP
Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
[TBL] [Abstract][Full Text] [Related]
52. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
53. Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade.
Wilkinson RW; Leishman AJ
Front Immunol; 2018; 9():1082. PubMed ID: 29910800
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy in elderly patients: should we stay or should we go?
Nunno VD; Franceschi E; Brandes AA
Future Oncol; 2020 May; 16(15):973-974. PubMed ID: 32285699
[No Abstract] [Full Text] [Related]
55. Avelumab and other recent advances in Merkel cell carcinoma.
Bommareddy PK; Kaufman HL
Future Oncol; 2017 Dec; 13(30):2771-2783. PubMed ID: 28976209
[TBL] [Abstract][Full Text] [Related]
56. [Not Available].
Pasqualini C; Rialland F; Valteau-Couanet D; Michon J; Minard-Colin V
Bull Cancer; 2018 Dec; 105 Suppl 1():S68-S79. PubMed ID: 30595201
[TBL] [Abstract][Full Text] [Related]
57. Immunotherapy of Cancer Visualized by Live Microscopy: Seeing Is Believing.
Teijeira A; Etxeberria I; Ponz-Sarvise M; Melero I
Clin Cancer Res; 2016 Sep; 22(17):4277-9. PubMed ID: 27330056
[TBL] [Abstract][Full Text] [Related]
58. [Combinations of chemotherapy or radiotherapy with checkpoint inhibitors].
Ghiringhelli F
Biol Aujourdhui; 2018; 212(3-4):77-79. PubMed ID: 30973135
[TBL] [Abstract][Full Text] [Related]
59. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
Shim H
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
[TBL] [Abstract][Full Text] [Related]
60. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
